CytoMed Therapeutics (GDTC) Payables (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Payables for 5 consecutive years, with $373994.6 as the latest value for Q4 2025.

  • Quarterly Payables rose 3.93% to $373994.6 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $373994.6 through Dec 2025, up 3.93% year-over-year, with the annual reading at $370999.5 for FY2025, 5.89% up from the prior year.
  • Payables hit $373994.6 in Q4 2025 for CytoMed Therapeutics, up from $359855.1 in the prior quarter.
  • In the past five years, Payables ranged from a high of $541269.6 in Q4 2022 to a low of $359855.1 in Q4 2024.
  • Historically, Payables has averaged $426845.3 across 5 years, with a median of $413713.8 in 2023.
  • Biggest five-year swings in Payables: increased 21.53% in 2022 and later decreased 23.57% in 2023.
  • Year by year, Payables stood at $445393.4 in 2021, then rose by 21.53% to $541269.6 in 2022, then dropped by 23.57% to $413713.8 in 2023, then fell by 13.02% to $359855.1 in 2024, then increased by 3.93% to $373994.6 in 2025.
  • Business Quant data shows Payables for GDTC at $373994.6 in Q4 2025, $359855.1 in Q4 2024, and $413713.8 in Q4 2023.